Pediatric Myocarditis: What Have We Learnt So Far?

被引:12
|
作者
Pomiato, Elettra [1 ]
Perrone, Marco Alfonso [1 ]
Palmieri, Rosalinda [1 ]
Gagliardi, Maria Giulia [1 ]
机构
[1] Bambino Gesu Pediat Hosp, Dept Pediat Cardiol & Cardiac Surg, IRCCS, I-00165 Rome, Italy
关键词
myocarditis; children; endomyocardial biopsy; inflammatory cardiomyopathy; immune system; GIANT-CELL MYOCARDITIS; CARDIOVASCULAR MAGNETIC-RESONANCE; ENDOMYOCARDIAL BIOPSY; FOLLOW-UP; DILATED CARDIOMYOPATHY; UNITED-STATES; IMMUNOSUPPRESSIVE THERAPY; CLINICAL PRESENTATION; CIRCULATORY SUPPORT; REPAIRED TETRALOGY;
D O I
10.3390/jcdd9050143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocarditis is an inflammatory disease of the myocardium that is troublesome to diagnose and manage, especially in children. Since the introduction of endomyocardial biopsy (EMB), new diagnostic tools have provided useful data. Especially when enhanced with immunohistochemistry and polymerase chain reaction (PCR) studies, EMB remains the gold standard for the diagnosis. Notably, cardiac magnetic resonance (MRI) is a non-invasive tool that can confirm the diagnosis and has a particular usefulness during the follow-up. The causes of myocarditis are heterogeneous (mostly viral in children). The course and outcome of the illness in the pediatric population represent a complex interaction between etiologic agents and the immune system, which is still not fully understood. The clinical presentation and course of myocarditis vary widely from paucisymptomatic illness to acute heart failure refractory to therapy, arrhythmias, angina-like presentation and sudden cardiac death. In this setting, cardiac biomarkers (i.e., troponins and BNP), although unspecific, can be used to support the diagnosis. Finally, the efficacy of therapeutic strategies is controversial and not confirmed by clinical trials. In this review, we summarized the milestones in diagnosis and provided an overview of the therapeutic options for myocarditis in children.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Levosimendan: What Have We Learned So Far?
    Villa, Giulia
    Tavazzi, Guido
    Guarracino, Fabio
    Sangalli, Fabio
    CURRENT ANESTHESIOLOGY REPORTS, 2019, 9 (03) : 234 - 241
  • [42] THE INTRODUCTION OF A ROBOTICS PROGRAMME TO SUPPORT SCHOOL ABSENCE: WHAT HAVE WE LEARNT FROM FAMILIES SO FAR?
    Kirk, Rebecca
    Willis, Susie
    Mccarthy, Anthony
    Andrews, Carla
    Klewchuk, Elaine
    Poland, Anna
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S408 - S408
  • [43] Role of biologics and other therapies in stricturing Crohn's disease: What have we learnt so far?
    Sorrentino, D.
    DIGESTION, 2008, 77 (01) : 38 - 47
  • [44] Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?
    Handy, Richard D.
    van den Brink, Nico
    Chappell, Mark
    Muehling, Martin
    Behra, Renata
    Dusinska, Maria
    Simpson, Peter
    Ahtiainen, Jukka
    Jha, Awadhesh N.
    Seiter, Jennifer
    Bednar, Anthony
    Kennedy, Alan
    Fernandes, Teresa F.
    Riediker, Michael
    ECOTOXICOLOGY, 2012, 21 (04) : 933 - 972
  • [45] Sex chromosome systems in Neotropical Primates: What have we learnt so far from cytogenetics and genomics?
    Steinberg, Eliana Ruth
    Bressa, Maria Jose
    Mudry, Marta Dolores
    JOURNAL OF EVOLUTIONARY BIOLOGY, 2022, 35 (12) : 1589 - 1600
  • [46] Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
    Lazarevic, Ivana
    Pravica, Vera
    Miljanovic, Danijela
    Cupic, Maja
    VIRUSES-BASEL, 2021, 13 (07):
  • [47] Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?
    Richard D. Handy
    Nico van den Brink
    Mark Chappell
    Martin Mühling
    Renata Behra
    Maria Dušinská
    Peter Simpson
    Jukka Ahtiainen
    Awadhesh N. Jha
    Jennifer Seiter
    Anthony Bednar
    Alan Kennedy
    Teresa F. Fernandes
    Michael Riediker
    Ecotoxicology, 2012, 21 : 933 - 972
  • [48] THE LEEDS POST COVID-19 REHABILITATION PATHWAY; WHAT WE HAVE LEARNT AND ACHIEVED SO FAR
    Chisman, E.
    France, S.
    McCormick, S.
    Shardha, J.
    BRITISH JOURNAL OF OCCUPATIONAL THERAPY, 2021, 84 (8_SUPPL) : 1 - 1
  • [49] Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? (vol 34, pg 19, 2015)
    Torres, A.
    Bonanni, P.
    Hryniewicz, W.
    Moutschen, M.
    Reinert, R. R.
    Welte, T.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (02) : 415 - 416
  • [50] Update on myocarditis - what we know so far and where we may be heading
    Rroku, Andi
    Kottwitz, Jan
    Heidecker, Bettina
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2021, 10 (04) : 455 - 467